Prophylactic and Therapeutic Breast Conservation in BRCA1/2 Mutation Carriers

Area of Science:

• Oncology
• Surgical Oncology
• Genetics

Background:

• Breast-conserving therapy (BCT) is a standard treatment for sporadic breast cancer, offering comparable survival to mastectomy despite a higher risk of ipsilateral breast tumor recurrence (IBTR).
• Women with BRCA1/2 mutations often choose mastectomy due to concerns about aggressive disease, but evidence supporting this choice over BCT is lacking.
• BRCA1/2-associated breast cancers are not inherently more aggressive or treatment-resistant than sporadic tumors.

Purpose of the Study:

• To review the current literature on breast conservation in BRCA1/2 mutation carriers.
• To inform surgical decision-making for breast cancer patients with BRCA1/2 mutations.

Main Methods:

• Literature review of studies comparing breast-conserving therapy and mastectomy in BRCA1/2 mutation carriers.
• Analysis of evidence regarding tumor aggressiveness and treatment outcomes in BRCA1/2-associated breast cancer.

Main Results:

• No definitive evidence shows BRCA1/2-associated breast cancer is more aggressive or resistant to treatment.
• No survival advantage for mastectomy has been demonstrated in appropriately treated BRCA1/2 mutation carriers.
• Studies do not provide strong evidence against offering breast conservation to these women.

Conclusions:

• Breast conservation is a viable option for BRCA1/2 mutation carriers with breast cancer.
• Surgical decisions should be individualized, considering the available evidence on BCT and mastectomy outcomes.
• Further research is needed to fully elucidate the long-term outcomes of BCT in BRCA1/2 carriers.